| Literature DB >> 35635615 |
Kok-Yong Chin1, Kok-Lun Pang2, Sok Kuan Wong3, Deborah Chia Hsin Chew4, Haji Mohd Saad Qodriyah3.
Abstract
Vitamin K is essential for the carboxylation of the vitamin K-dependent proteins that are responsible for the suppression of matrix calcification. The use of vitamin K antagonists (VKAs) in patients with cardiovascular diseases could affect protein carboxylation and lead to the development of osteoarthritis (OA). This review aims to summarise the current evidence for the relationship between VKAs and OA. The literature search revealed that in observation studies, good vitamin K status, as reflected by the circulating level or protein carboxylation status of vitamin K, is associated positively with improved joint structural and functional indices and negatively associated with OA incidence. By contrast, in limited retrospective and prospective studies, the use of VKAs is associated positively with OA occurrence and knee/hip replacement. Pharmacological interactions between VKAs and various OA therapeutic agents exist and require careful monitoring and dosing. In conclusion, further epidemiological studies are warranted to verify the relationship between VKA use and OA to strengthen the evidence. Given that VKA use exerts potentially negative effects on joint health, intervention is required to protect the quality of life and mobility of patients.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35635615 DOI: 10.1007/s40266-022-00945-y
Source DB: PubMed Journal: Drugs Aging ISSN: 1170-229X Impact factor: 4.271